Product Description
Dasatinib is used to treat a certain type of chronic myeloid leukemia (CML; a type of cancer of the white blood cells) as a first treatment and in people who can no longer benefit from other leukemia medications including imatinib (Gleevec) or in those who cannot take these medications because of side effects. Dasatinib is also used to treat a certain type of chronic CML in children. Dasatinib is also used to treat a certain type of acute lymphoblastic leukemia (ALL; a type of cancer of the white blood cells) in people who can no longer benefit from other leukemia medications or who cannot take these medications because of side effects. Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a607063.html)
Mechanisms of Action: TK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: Eastern America
Company Founding Year: 1989
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Jordan, Korea, Lebanon, Malaysia, Netherlands, Norway, Portugal, Russia, Saudi Arabia, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan, Tunisia, United Kingdom, United States, Vietnam
Active Clinical Trial Count: 23
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Lymphoid Leukemia|Chronic Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phase 2: Acute Myeloid Leukemia|B-Cell Leukemia|Bone Diseases, Metabolic|Breast Cancer|Chronic Lymphoid Leukemia|HIV Infections|Leukemia|Lymphoma, B-Cell|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Osteoporosis|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Prostate Cancer|T-Cell Leukemia|T-Cell Peripheral Lymphoma
Phase 1: Blast Crisis|Burkitt Lymphoma|Healthy Volunteers|Leukemia, Plasma Cell|Lymphoma, Non-Hodgkin|Multiple Myeloma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03595917 |
NCT03595917 | P1 |
Recruiting |
Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Blast Crisis|Acute Lymphoid Leukemia|Chronic Lymphoid Leukemia|B-Cell Leukemia|Lymphoma, B-Cell|Burkitt Lymphoma|Myelogenous, Chronic, BCR-ABL Positive Leukemia |
2026-11-01 |
12% |
2025-11-05 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT04603872 |
DASA001 | P1 |
Recruiting |
Acute Lymphoid Leukemia|Multiple Myeloma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Plasma Cell|Lymphoma, Non-Hodgkin |
2023-11-01 |
59% |
2020-10-28 |
Primary Endpoints|Treatments |
NCT05751044 |
HEM-iSMART B | P2 |
Recruiting |
T-Cell Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|B-Cell Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia|Lymphoma, B-Cell |
2032-02-01 |
2% |
2025-09-17 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
NCT06390319 |
SJALL23T | P2 |
Recruiting |
T-Cell Peripheral Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|T-Cell Leukemia|Acute Lymphoid Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma |
2027-12-01 |
12% |
2025-02-04 |
Patient Enrollment|Primary Endpoints|Treatments |
NCT05007873 |
NCI-2021-08486 | P2 |
Recruiting |
Chronic Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia |
2026-10-30 |
12% |
2024-08-28 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06018467 |
SENIOR | P2 |
Active, not recruiting |
Bone Diseases, Metabolic|Osteoporosis |
2026-04-30 |
50% |
2026-01-29 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2021-001288-26 |
2021-001288-26 | P2 |
Active, not recruiting |
HIV Infections |
2024-07-29 |
|||
NCT01471106 |
NCI-2012-00037 | P2 |
Completed |
Breast Cancer |
2024-01-31 |
61% |
2024-07-11 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
NCT01254864 |
NCI-2011-00267 | P2 |
Completed |
Prostate Cancer |
2023-12-07 |
47% |
2023-12-16 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT03117751 |
TOT17 | P3 |
Active, not recruiting |
Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2026-09-30 |
10% |
2024-11-27 |
Primary Endpoints|Treatments |
jRCT2021210060 |
jRCT2021210060 | P3 |
Active, not recruiting |
Chronic Myeloid Leukemia |
2029-03-31 |
|||
NCT03020030 |
NCT03020030 | P3 |
Active, not recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia |
2026-11-30 |
40% |
2025-01-04 |
|
NCT06257394 |
VHR ALL | P2 |
Recruiting |
Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2034-12-31 |
2025-06-10 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
2010-019119-39 |
GIMEMA Study LAL1509 | P2 |
Completed |
Acute Lymphoid Leukemia |
2024-12-31 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
2024-510784-36-00 |
CA180-226 | P2 |
Completed |
Chronic Myeloid Leukemia |
2024-10-25 |
2025-05-02 |
Treatments |
|
NCT04872790 |
STUDY00022691 | P1 |
Recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia |
2026-12-02 |
50% |
2026-02-12 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06145217 |
XS004-17 | P1 |
Completed |
Healthy Volunteers |
2023-08-22 |
2023-11-27 |
Primary Endpoints|Treatments |
|
NCT03625388 |
LPI-JOR-LEB-KSA-TUN-2017-01 | P2 |
Completed |
Chronic Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia |
2023-07-22 |
55% |
2023-09-23 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2016-004106-34 |
2016-004106-34 | P2 |
Completed |
Chronic Myeloid Leukemia |
2023-02-01 |
2025-07-05 |
Treatments |
|
CTR20132365 |
CTR20132365 | P2 |
Recruiting |
Chronic Myeloid Leukemia|Acute Lymphoid Leukemia|Chronic Lymphoid Leukemia|Acute Myeloid Leukemia |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20131053 |
CTR20131053 | P2 |
Active, not recruiting |
Leukemia |
None |
2025-04-29 |
Treatments |
|
2015-003502-16 |
DasaHIT | P3 |
Completed |
Chronic Myeloid Leukemia |
2023-03-31 |
2025-07-04 |
Treatments |
|
NCT06533748 |
SJALL23H | P2 |
Recruiting |
Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2028-05-01 |
12% |
2025-01-11 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/10/2026 |
News Article |
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results |
|
01/09/2026 |
News Article |
ACTG Launches IPACE-HIV to Study Frailty Intervention |
|
02/02/2026 |
News Article |
Lupin Launches Dasatinib Tablets in the United States |
|
01/30/2026 |
News Article |
Immunocore announces R&D leadership evolution |
